



PATENT

Case Docket No. STERN1.001APC

Date: November 1, 2002


Page 1

In re application of : Lubbert, Hermann  
App. No. : 09/830,703  
Filed : April 26, 2001  
For : TRANSGENIC ANIMAL MODEL  
FOR NEURODEGENERATIVE  
DISEASES  
Examiner : Qian, C. X.  
Art Unit : 1636

) I hereby certify that this correspondence and all  
marked attachments are being deposited with the  
United States Postal Service as first class mail in  
an envelope addressed to: United States Patent  
and Trademark Office, P.O. 2327, Arlington, VA  
22202, on

November 1, 2002

(Date)

  
Mark R. Benedict, Reg. No. 44,531

UNITED STATES PATENT AND TRADEMARK OFFICE  
P.O. Box 2327  
Arlington, VA 22202

RECEIVED

NOV 6 2002

TECH CENTER 2000

Sir:

Transmitted herewith is a *Response to Restriction Requirement and Amendment* in the above-identified application.

(X) An extension of time to respond for three months is hereby requested.

Time Extension Fee:

(X) three months (\$460 small entity)

The fee has been calculated as shown below:

CLAIMS AS FILED

CLAIMS REMAINING AFTER AMENDMENT	HIGHEST NO. PREVIOUSLY PAID FOR	PRESENT EXTRA	RATE	ADDITIONAL FEE
Total Claims 24 —	24	= 0	\$9	= \$0
Independent Claims 2 —	3	= 0	\$42	= \$0
If application has been amended to contain multiple dependent claim(s), then add			\$140	= \$0
Time Extension Fee				\$460
			TOTAL ADDITIONAL FEE FOR THIS AMENDMENT	\$460

Case Docket No. STERN1.001APC

Date: November 1, 2002

Page 2

---

- (X) The present application qualifies for small entity status under 37 C.F.R. § 1.27.
- (X) Return prepaid postcard.
- (X) A check in the amount of \$460 is enclosed.
- (X) Please charge any additional fees, including any fees for additional extension of time, or credit overpayment to Deposit Account No. 11-1410.



---

Mark R. Benedict  
Registration No. 44,531  
Attorney of Record  
Customer No. 20,995  
(949) 760-0404

O:\DOCS\MXG\MXG-1718.DOC\vb  
103002

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : Lubbert, Hermann  
 Appl. No. : 09/830,703  
 Filed : April 26, 2001  
 For : TRANSGENIC ANIMAL  
       MODEL FOR  
       NEURODEGENERATIVE  
       DISEASES  
 Examiner : Qian, Celine X.

Group Art Unit: 1636

RECEIVED

NOV 08 2002

TECH CENTER 1600/2900

RESPONSE TO RESTRICTION REQUIREMENT  
AND  
AMENDMENT

United States Patent and Trademark Office  
 P.O. Box 2327  
 Arlington, VA 22202

Dear Sir:

This is in response to Restriction Requirement set forth in the Office Action, mailed July 2, 2002.

IN THE CLAIMS:

**Please amend Claims 8 and 14 as follows:**

8. **(Twice amended)** A transgenic non-human mammal comprising an isolated or purified polynucleotide encoding a mutant mouse parkin2 protein, or a homolog thereof, wherein said mutant causes symptoms of Parkinson's disease.

14. **(Twice amended)** A method of producing a transgenic animal, comprising:

constructing a vector that carries an isolated or purified polynucleotide encoding a mutant mouse parkin2 protein, or a homolog thereof, wherein said mutant causes symptoms of Parkinson's disease;

introducing said vector into embryonic stem cells;

Appl. No. : 09/830,703  
Filed : April 26, 2001

injecting said embryonic stem cells into blastocysts; and  
placing said blastocysts into a pseudopregnant female animal.

**REMARKS**

**Independent Inventions Restriction**

In response to the Restriction Requirement, Applicant elects with traverse, Group III (Claims 8, 14, 15, 22, and 29). In addition, Applicant would like to request rejoinder of claims from groups IV and V (Claims 17, 18, 20, 30, and 32), which are dependent on the generic Claim 8 with the understanding that upon the allowance of the linking claim (Claim 8), applicant will be entitled to consideration of claims 17, 18, 20, 30, and 32 which are written in dependent form. This election is made with traverse.

**Amendments**

The specific changes to the amended claims are shown on a separate page attached hereto and entitled **VERSION WITH MARKINGS TO SHOW CHANGES MADE**, which follows the signature page of this Amendment. On this page, the insertions are double underlined while the deletions are struck through.


Please charge any fees, including any fees for extension of time, to Deposit Account No. 11-1410.

Respectfully submitted,

KNOBBE, MARTENS, OLSON & BEAR, LLP

Dated: 11/1/02

By:

  
Mark R. Benedict  
Registration No. 44,531  
Attorney of Record  
Customer No. 20,995  
(949) 760-0404

VERSION WITH MARKINGS TO SHOW CHANGES MADE

8. **(Twice amended)** A transgenic non-human mammal comprising the an isolated or purified polynucleotide of claim 1 encoding a mutant mouse parkin2 protein, or a homolog thereof, wherein said mutant causes symptoms of Parkinson's disease.
14. **(Twice amended)** A method of producing a transgenic animal, comprising:  
constructing a vector that carries the an isolated or purified polynucleotide of claim 1 encoding a mutant mouse parkin2 protein, or a homolog thereof, wherein said mutant causes symptoms of Parkinson's disease;  
introducing said vector into embryonic stem cells;  
injecting said embryonic stem cells into blastocysts; and  
placing said blastocysts into a pseudopregnant female animal.